Attorney Docket No.: PR60714USw

Amendments to the Claims:

Please amend the claims as follows:

1. (Currently Amended) A compound of Formula (I) or a salt or solvate thereof:

wherein:

- R1 is hydrogen or C₁₋₆alkyl or as indicated by the dotted line is fused to the phenyl forming a 5 or 6 membered ring, optionally containing a double bond;
- n is 0, 1, 2, 3 or 4;
- R2 is aryl, optionally substituted by one or two groups selected from the group consisting of halogen, NH₂, hydroxy, cyano, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, haloC₁₋₄alkyl, haloC₁₋₄alkoxy, aryl, aryloxy, C₁₋₄alkoxycarbonyl, C₁₋₄alkylsulfonyl and a group R₃R₄NSO₂ (wherein R₃ and R₄ are independently hydrogen or C₁₋₄alkyl), (CH₂)₀₋₃NHCOOC₁₋₄alkyl, and a 5- or 6-membered heteroaryl group;
- or n is 0 and R1 and R2, together with the nitrogen atom to which they are joined, form a 5- or 6-membered monocyclic heterocyclic ring or a 9- or 10-membered bicyclic heterocyclic ring wherein at least the ring which contains the nitrogen atom to which R1 and R2 are joined is non-aromatic, and wherein the 5- or 6-membered monocyclic heterocyclic ring or the 9- or 10-membered bicyclic heterocyclic ring is optionally substituted by one or two groups selected from the group consisting of halogen, hydroxy, cyano, oxo, C₁₋₄alkyl, C₁₋₄alkanoyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, haloC₁₋₄alkoxy, aryl, aryloxy and C₁₋₄alkoxycarbonyl; and
- X is indazelyl, pyrazelyl or a group

Attorney Docket No.: PR60714USw

wherein

G is CH or N; and

 Y_1 and Y_2 are independently hydrogen, halogen and a group NR5R6 (wherein R5 and R6 are independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, or

- 2. (Original) A compound as claimed in claim 1, wherein R1 is hydrogen.
- 3. (Previously Presented) A compound as claimed in claim 1, wherein n is 1 or 2.
- 4. (Previously Presented) A compound as claimed in claim 1, wherein R2 is aryl, optionally substituted by one or two groups selected from the group consisting of halogen and C_{1-4} alkoxy.
- 5. (Previously Presented) A compound as claimed in claim 1, wherein n is 0 and R1 and R2, together with the nitrogen atom to which they are joined, form a 6-membered monocyclic heterocyclic ring or a 10-membered bicyclic heterocyclic ring wherein at least the ring which each contains the nitrogen atom to which R1 and R2 are joined is non-aromatic, wherein the 6-membered monocyclic heterocyclic ring or 10-membered bicyclic heterocyclic ring are both optionally substituted by one or two groups selected from oxo, C₁-4alkyl, phenyl and C₁₋₄alkoxycarbonyl.
- 6-7. (Cancelled).
- 8. (Currently Amended) A compound as claimed in claim 1, wherein X is a group:

wherein one of Y_1 and Y_2 is hydrogen, and the other is hydrogen, halogen or a group NR5R6 whrein wherein R5 and R6 are independently hydrogen, C_{1-6} alkyl or C_{2-6} alkenyl.

9. (Currently Amended) A compound as claimed in claim 1, wherein said compound is selected from the group consisting of: N-benzyl-4-(4-pyridinyl)benzamide; N-(2-phenylethyl)-4-(4-pyridinyl)benzamide: N-(3-methoxybenzyl)-4-(4-pyridinyl)benzamide; N-(3-methoxybenzyl)-4-(1H-pyrazol-4-yl)benzamide; 4-(2-chloro-4-pyridinyl)-N-(3-methoxybenzyl)benzamide; 4-(2-amino-4-pyrimidinyl)-N-(3-methoxybenzyl)benzamide; N-(3-methoxybenzyl)-4-(4-pyrimidinyl)benzamide; 4-[6-(allylamino)-4-pyrimidinyl]-N-(3-methoxybenzyl)benzamide; 4-[6-amino-4-pyrimidinyl]-N-(3-methoxybenzyl)benzamide; 4-(1H-indazol-5-yl)-N-(3-methoxybenzyl)benzamide; 4-(2-amino-4-pyrimidinyl)-N-{[3-(methyloxy)phenyl]methyl}benzamide; 4-(2-{[4-(methyloxy)phenyl]amino}-4-pyrimidinyl)-N-{[3-(methyloxy)phenyl]methyl}benzamide; 4-(2-amino-4-pyrimidinyl)-N-[(2-chlorophenyl)methyl]benzamide; 4-(2-amino-4-pyrimidinyl)-N-[(4-fluorophenyl)methyl]benzamide; 4-(2-amino-4-pyrimidinyl)-N-[(4-chlorophenyl)methyl]benzamide; 4-(2-amino-4-pyrimidinyl)-N-[(2-fluorophenyl)methyl]benzamide; 4-(2-amino-4-pyrimidinyl)-N-{[2-(methyloxy)phenyl]methyl}benzamide; 4-(2-amino-4-pyrimidinyl)-N-[(2-methylphenyl)methyl]benzamide; 4-(2-amino-4-pyrimidinyl)-N-{[4-(methyloxy)phenyl]methyl}benzamide; 4-(2-amino-4-pyrimidinyl)-N-(2,3-dihydro-1H-inden-1-yl)benzamide; 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamide; 4-(2-amino-4-pyrimidinyl)-N-{[3-(trifluoromethyl)phenyl]methyl}benzamide; 1,1-dimethylethyl({3-[({[4-(2-amino-4pyrimidinyl)phenyl]carbonyl}amino)methyl]phenyl}methyl)carbamate; 4-(2-amino-4-pyrimidinyl)-N-[(3-bromophenyl)methyl]benzamide; 4-(2-amino-4-pyrimidinyl)-N-[(3-chlorophenyl)methyl]benzamide; 4-(2-amino-4-pyrimidinyl)-N-[(3-fluorophenyl)methyl]benzamide; 4-(2-amino-4-pyrimidinyl)-N-(phenylmethyl)benzamide; 4-(2-amino-4-pyrimidinyl)-N-{(1S)-1-[4-(methyloxy)phenyl]ethyl}benzamide;

4-(2-amino-4-pyrimidinyl)-N-[(1S)-1-phenylpropyl]benzamide;

6-(2-amino-4-pyrimidinyl)-2-(phenylmethyl)-1(2H)-isoquinolinone;

- 4-(2-amino-4-pyrimidinyl)-N-[(3-hydroxyphenyl)methyl]benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-({3-[(difluoromethyl)oxy]phenyl}methyl)benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-(1-methyl-1-phenylethyl)benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-[(3,5-dichlorophenyl)methyl]benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-(4-biphenylylmethyl)benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1-phenylethyl]benzamide;
- 1,1-dimethylethyl{3-[1-({[4-(2-amino-4-

pyrimidinyl)phenyl]carbonyl}amino)ethyl]phenyl}carbamate;

- N-[(2-aminophenyl)methyl]-4-(2-amino-4-pyrimidinyl)benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamide;
- 5-(2-amino-4-pyrimidinyl)-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one;
- 4-(2-amino-4-pyrimidinyl)-N-{(1R)-1-[3-(methyloxy)phenyl]ethyl}benzamide; and
- 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1-phenylpropyl]benzamide;

or a salt or solvate and salts thereof.

10 - 13. (Cancelled).

14. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in claim 1 and one or more of pharmaceutically acceptable carriers, diluents and excipients.